BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Igrelimogene litadenorepvec readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Igrelimogene litadenorepvec\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06961786-2767@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Igrelimogene litadenorepvec: Phase 1 readout est. (NCT06961786)
DESCRIPTION:Igrelimogene litadenorepvec\, phase 1.\nStudy: TNFα and IL-2 C
 oding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy
  and TILs in the Treatment of Melanoma\nEstimated primary completion: Nove
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/igrelimoge
 ne-litadenorepvec#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06961786
URL:https://assetmemo.bio/drug/igrelimogene-litadenorepvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05222932-2767@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Igrelimogene litadenorepvec: Phase 1 readout est. (NCT05222932)
DESCRIPTION:Igrelimogene litadenorepvec\, phase 1.\nStudy: Oncolytic Adenov
 irus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or 
 Progressing After Anti-PD(L)1\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/igrelimogene-litade
 norepvec#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05222932
URL:https://assetmemo.bio/drug/igrelimogene-litadenorepvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05271318-2767@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Igrelimogene litadenorepvec: Phase 1/2 readout est. (NCT05271318)
DESCRIPTION:Igrelimogene litadenorepvec\, phase 1/2.\nStudy: Oncolytic Aden
 ovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizu
 mab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment
  for Ovarian Cancer.\nEstimated primary completion: March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/igrelimogene-litadenorepvec#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0527131
 8
URL:https://assetmemo.bio/drug/igrelimogene-litadenorepvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
